Case-report: EBV driven lymphoproliferative disorder associated with Ruxolitinib.

Research output: Contribution to journalArticle

Abstract

Ruxolitinib, a novel inhibitor of Janus kinases 1 and 2, was recently approved for the treatment of myelofibrosis but, recently, attention has been drawn to potential side effects and especially opportunistic infections and virus reactivations. EBV reactivation has not previously been reported to occur in association with Ruxolitinib.

Details

Authors
Organisations
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Hematology
Original languageEnglish
Pages (from-to)10
JournalBMC Hematology
Volume15
Publication statusPublished - 2015
Publication categoryResearch
Peer-reviewedYes